Zimmer Biomet (NYSE:ZBH)‘s stock had its “hold” rating reiterated by Canaccord Genuity in a research note issued to investors on Friday, January 5th. They presently have a $132.00 price objective on the medical equipment provider’s stock. Canaccord Genuity’s target price suggests a potential upside of 3.84% from the stock’s previous close.
ZBH has been the subject of several other research reports. Royal Bank of Canada lowered their price objective on shares of Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, November 7th. Zacks Investment Research lowered shares of Zimmer Biomet from a “hold” rating to a “sell” rating in a research note on Monday, November 6th. BMO Capital Markets decreased their price target on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday, November 2nd. Jefferies Group restated a “buy” rating and set a $136.00 price target on shares of Zimmer Biomet in a research note on Friday, November 3rd. Finally, Deutsche Bank upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a research note on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $141.37.
Shares of Zimmer Biomet (NYSE:ZBH) opened at $127.12 on Friday. The firm has a market cap of $25,740.00, a price-to-earnings ratio of 14.09, a PEG ratio of 1.99 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.47 and a quick ratio of 0.78. Zimmer Biomet has a one year low of $108.03 and a one year high of $133.49.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting the consensus estimate of $2.10. The company had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. Zimmer Biomet’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.14 EPS. analysts expect that Zimmer Biomet will post 8.03 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Kornitzer Capital Management Inc. KS bought a new stake in shares of Zimmer Biomet in the 4th quarter worth $314,000. Wedge Capital Management L L P NC grew its stake in shares of Zimmer Biomet by 0.6% in the 4th quarter. Wedge Capital Management L L P NC now owns 1,458,413 shares of the medical equipment provider’s stock worth $175,987,000 after acquiring an additional 8,116 shares in the last quarter. Dean Capital Investments Management LLC bought a new stake in shares of Zimmer Biomet in the 4th quarter worth $429,000. Mutual of America Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 5.4% in the 4th quarter. Mutual of America Capital Management LLC now owns 35,932 shares of the medical equipment provider’s stock worth $4,336,000 after buying an additional 1,831 shares during the last quarter. Finally, Dupont Capital Management Corp boosted its holdings in shares of Zimmer Biomet by 3.9% in the 4th quarter. Dupont Capital Management Corp now owns 87,645 shares of the medical equipment provider’s stock worth $10,576,000 after buying an additional 3,323 shares during the last quarter. Hedge funds and other institutional investors own 86.20% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/01/zimmer-biomet-zbh-receives-hold-rating-from-canaccord-genuity.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.